Furthermore, most HNSCC clinical trials evaluating anti-EGFR therapies were performed in unselected populations where EGFR CNV or EGFR overexpression using immunohistochemistry was not investigated (49). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.